ClinicalTrials.gg
CompletedNCT00668304SPEEDUpdated Dec 19, 2014

Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox

A Phase 4 interventional study of Avelox (Moxifloxacin, BAY12-8039) in Maxillary Sinusitis, sponsored by Bayer. Completed at 35 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-19.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
192
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 129 studies in Sinusitis with a site in United States — 6 open to participants now, 12 under way, none of them phase 3. Sinusitis · United States.

Enrollment
17th of 103
192 · median 44
Started
2004
with 1 other
Phase 4
23 of 129
3 open now
Registered
29th of 129
by date
Lead sponsor
2 of 129
Bayer

Among the 129 studies in Sinusitis with a site in United States, this one is the 17th largest by enrollment of the 103 interventional ones that give a count, is one of 2 that started in 2004, is one of 23 in phase 4, and was the 29th registered.

Sinusitis

256 studies on the registry are indexed under Sinusitis; 23 are open to participants now.

Browse Sinusitis studies →

Open to participants now

6 of the 129 studies in Sinusitis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Sinusitis studies recruiting now, 6 (40%) set no upper age limit and 6 (40%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Sinusitis with a site in United States, or all of them as a file.
02

Study summary

This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.

03

Conditions studied

  • Maxillary Sinusitis

Browse trials for

Keywords

  • Sinusitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of acute sinusitis with signs and symptoms present for >7 days but \< 28 days as defined by A), radiographic, and B) clinical criteria, as follows:a. The presence of 1 or more of the following on a radiographic paranasal sinus film (Waters' view) or limited CT scan:** evidence of air-fluid levels** opacification. The presence of at least one major and one minor symptom as defined in the list below:** Major Symptoms*** Purulent anterior or posterior nasal discharge*** Unilateral moderate or severe facial pain or malar tenderness** Minor Symptoms*** Cough or frequent throat clearing*** Frontal headache*** Halitosis*** Fever (oral > 38.0°C/100.4°F, tympanic > 38.5°C/101.2°F)*** Purulent secretions obtained via middle meatus secretion sampling using nasal endoscopic technique; the specimen sent for Gram stain, culture and susceptibility testing prior to initiation of antimicrobial therapy

Exclusion criteria

Exclusion Criteria:

  • History of chronic sinusitis defined as greater than four weeks of continuous symptoms (patients with history of sinus surgery may be included; patients with recurrent sinusitis may be included)
  • Known bacteremia, meningitis or infection infiltrating the tissues neighboring the sinuses- Received systemic antibacterial therapy likely to be effective in sinusitis for more than 24 hours within 7 days of enrollment- A requirement for concomitant systemic antibacterial therapy with agents other than those specified in this protocol- Known immunodeficiency diseases including AIDS (CD4 \<200)- On topical nasal or systemic , unless they have been on a stable dose for > 4 weeks prior to enrollment- History of allergy to quinolone antibiotics or related compounds- Pregnant or breast feeding- Of in whom pregnancy cannot be excluded by a negative pregnancy test and who are not using reliable barrier method of
  • Received an drug in the past 30 days- Unable to take oral medication- Known to have congenital or sporadic syndromes of prolongation or receiving concomitant medication reported to increase the QTc interval (e.g. amiodarone, sotalol, disopyramide, quinidine, procainamide, terfenadine)
  • End stage liver cirrhosis (class C)- Severe renal impairment requiring dialysis
  • Previous history of tendinopathy associated with quinolones- Any symptoms that suggest that the patient's current illness is allergic rhinitis (e.g., repetitive sneezing, itchy nose or eyes, provocation by an allergen) and not acute bacterial sinusitis
  • Diagnosis of rapidly fatal illness with a life expectance of less than 6 months- Previously enrolled in this clinical study- Uncorrected hypokalaemia
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to bacteriological eradication in those who are microbiologically valid for S. pneumoniae, M. catarrhalis, and H. influenzae

    Time frame: Days 1, 2, 3 of treatment

Secondary outcomes

  1. Patient-reported symptom improvement using SNOT-16 questionnaire

    Time frame: Up to End of Treatment (Day 10-13)

  2. Clinical Response

    Time frame: End of Treatment

  3. Bacteriological Response

    Time frame: End of Treatment

  4. Activity Impairment Assessment questionnaire

    Time frame: Up to End of Treatment (Day 10-13)

  5. Incidence of Premature Termination

    Time frame: Premature Termination

  6. Adverse Events Collection

    Time frame: Up to End of Treatment (Day 10-13)

07

Study locations

35 sites
  • Birmingham, Alabama 35206, United States
  • Hoover, Alabama 35216-5453, United States
  • Jonesboro, Arkansas 72401, United States
  • Searcy, Arkansas 72143, United States
  • Fresno, California 93720, United States
  • Riverside, California 92506, United States
  • San Francisco, California 94102, United States
  • Colorado Springs, Colorado 80909, United States
  • Longmont, Colorado 80501, United States
  • Bridgeport, Connecticut 06606, United States
  • DeLand, Florida 32720-2560, United States
  • Shreveport, Louisiana 71105, United States
  • Detroit, Michigan 48202, United States
  • North Massapequa, New York 11758, United States
  • Rochester, New York 14618, United States
  • Columbus, Ohio 43235, United States
  • Oklahoma City, Oklahoma 73120, United States
  • Yukon, Oklahoma 73099, United States
  • Lake Oswego, Oregon 97035, United States
  • Harrisburg, Pennsylvania 17110, United States
  • Greenville, South Carolina 29607, United States
  • Orangeburg, South Carolina 29118, United States
  • Jackson, Tennessee 38301, United States
  • Carrollton, Texas 75010, United States
  • Salt Lake City, Utah 84102, United States
  • Charlottesville, Virginia 22902, United States
  • Richmond, Virginia 23229, United States
  • Winchester, Virginia 22601, United States
  • Spokane, Washington 99202-1334, United States
  • Florencio Varela, Buenos Aires 1888, Argentina
  • Buenos Aires, Capital Federal 1416, Argentina
  • Buenos Aires, Capital Federal C1280AEB, Argentina
  • Rosario, Santa Fé 2000, Argentina
  • San Miguel de Tucumán, Tucumán 4000, Argentina
  • Córdoba, 5000, Argentina
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2008
First posted
Apr 29, 2008
Start
Jun 2004
CompletionActual
Jan 2005
Last update
Dec 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00668304
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 29, 2008
Start date
Jun 2004
Completion
Jan 2005
Last update
Dec 19, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion